CD274 and non-small cell lung carcinoma: However, contrasting results were reported in a cohort study from Japan, which included 15 patients with NSCLC who received PD-1 inhibitors, as crossover therapy after first-line PD-L1 inhibitor treatment did not demonstrate significant survival benefits.